Biotech EPS UP 8.58%, Price DOWN 9.52%
Summary
- The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In the spreadsheet above I have tracked the earnings estimates for the Nasdaq Biotech ETF (IBB) top 30 weighted stocks. The column under the date 9/9/2019 has a letter that represents the movement in 2019 earnings estimates since the most recent print (7/11/2019). “U” means 2019 estimates are UP in the last 60 days. “D” means 2019 estimates are DOWN in the last 60 days. “S” means 2019 estimates have remained the SAME in the last 60 days. The column entitled “1yr Target Est” is the Wall Street consensus 12 month price target for each stock. You can see how it has come up or come down in recent weeks.
What this table is telling us is that estimates have jumped up in the past 60 days. More estimates went UP for 2019 in the past 60 days than came DOWN 22:7 ratio. The rest remained the same.
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days. While it has had among the largest sector EPS increases, it has had among the worst price performance (dropping -9.5% peak to trough). Sooner or later these divergences tend to resolve themselves.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.